^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Thymus Cancer

Related cancers:
2d
Confronting Upside-Down Video-Assisted Thoracic Surgery for Anterior Mediastinal Leiomyoma. (PubMed, Surg Case Rep)
Primary leiomyoma of the anterior mediastinum is extremely rare. Because primary mediastinal leiomyomas have nonspecific imaging features, distinguishing them from other anterior mediastinal tumors is challenging; thus, surgical resection is required for both diagnosis and treatment. Compared with the conventional look-up method, the confronting upside-down VATS technique utilizes higher intercostal access to provide a comprehensive thoracic view while minimizing diaphragmatic interference. The 180-degree rotated assistant monitor allows both surgeon and assistant to share a thoracotomy-like visual field, enhancing intraoperative coordination. In this case, it facilitated a stable operative field and phrenic nerve preservation despite the tumor's proximity without diaphragmatic interference. The confronting upside-down VATS technique may be particularly advantageous for anterior mediastinal tumors located along the phrenic nerve and in close proximity to the diaphragm.
Journal • Video
|
CD34 (CD34 molecule)
6d
Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection (clinicaltrials.gov)
P=N/A, N=50, Active, not recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting --> Active, not recruiting
Enrollment closed
10d
Clinical characteristics and peripheral immune profile analysis of thymoma-associated myasthenia gravis with anti-titin antibodies: a multicenter, retrospective study. (PubMed, J Formos Med Assoc)
Anti-titin antibodies positive TAMG is associated with more severe disease-especially bulbar involvement. NLR, PLR, IL-2, IL-6, IL-8, and TNF-α are candidate biomarkers of severity.
Retrospective data • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • TTN (Titin) • IL2 (Interleukin 2) • IL1B (Interleukin 1, beta)
10d
Envafolimab combined with chemotherapy in advanced thymic carcinoma - first clinical experience with a novel subcutaneous programmed death-ligand 1 inhibitor. (PubMed, Anticancer Drugs)
We report two cases of advanced thymic carcinoma treated with the programmed death-ligand 1 inhibitor envafolimab with chemotherapy (liposomal paclitaxel and cisplatin)...Both patients achieved PFS (6 and 9 months, respectively) that exceeded the median PFS reported in previous clinical studies using chemotherapy alone (5 months). This combination warrants further investigation in clinical trials.
Journal • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1)
|
paclitaxel • Enweida (envafolimab)
14d
Atypical lung carcinoid with prominent mucinous stroma: unusual pathologic finding in pulmonary carcinoid. (PubMed, Oxf Med Case Reports)
This case represents a rare morphologic variant of AC distinguished by a prominent mucinous stroma, a feature that may obscure the diagnosis by simulating other mucin-producing lung tumors. Recognizing this uncommon pattern is crucial, as it directly impacts diagnostic accuracy and subsequent clinical decision-making.
Journal
|
NKX2-1 (NK2 Homeobox 1) • CDX2 (Caudal Type Homeobox 2) • SYP (Synaptophysin)
15d
Enrollment closed • Enrollment change
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • sunitinib
19d
Thymic health and immunotherapy outcomes in patients with cancer. (PubMed, Nature)
Analysis across patients with melanoma, breast cancer or renal cancer demonstrated pan-cancer relevance. Together, these findings identify thymic health as a previously unrecognized, tumour-agnostic determinant of immunotherapy efficacy, with potential implications for patient stratification, treatment timing and the development of immune-rejuvenating strategies in precision immuno-oncology.
Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
19d
Thymic Cyst: A Clinicopathological, Immunohistochemical, and Molecular Study of 36 Cases Focusing on Squamous- and Ciliated-Type Epithelium. (PubMed, Hum Pathol)
Based on morphological features, thymic cysts mainly comprise two types, SC-type and CC-type, which differ in their sizes, locularity, immunophenotypes, and CT features.
Journal
|
TP63 (Tumor protein 63)
20d
New P2 trial
|
cisplatin • albumin-bound paclitaxel • AiRuiLi (adebrelimab)
21d
An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins. (PubMed, JAMA Netw Open)
In this cross-sectional study of patients diagnosed with lung SCC, a meaningful number of patients experienced misdiagnosis, which was identified using a multipronged AI-assisted approach. Diagnosis changes prompted by AI and orthogonal evidence may assist clinicians in prognostication and therapy selection.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD5 (CD5 Molecule) • GATA3 (GATA binding protein 3)
21d
Brief Report: Androgen Receptor Expression Is Associated With Male Predominance in Thymic Neuroendocrine Neoplasms. (PubMed, JTO Clin Res Rep)
The AR is expressed in a considerable fraction of thymic neuroendocrine neoplasms and is associated with male predominance. This observation has implications for investigation of androgen deprivation and receptor blockade.
Journal
|
AR (Androgen receptor) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1)
21d
Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy. (PubMed, Cancer Immunol Immunother)
Finally, we review rational therapeutic strategies such as vascular endothelial growth factor-tyrosine kinase inhibitors-ICI combinations, radiotherapy-ICI approaches, perioperative immunotherapy, and emphasize the need for biomarker-enriched trial design. TETs provide a powerful model to understand how failure of central tolerance can simultaneously sensitize tumors to immune attack and prime patients for catastrophic toxicity, with implications that extend to other low-TMB, immune-infiltrated malignancies.
Review • Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden)
|
TMB-L